


example, on page 123, lines 1-20. Support for use in the detection of lung cancer is provided throughout the specification including, for example, on page 148, lines 14-15, and support for specific biological samples is provided, for example, on page 122, lines 21-22.

Attached hereto is a marked-up version of the changes made to the claims by the current amendment. The attached page is captioned "**Version With Markings to Show Changes Made.**" Applicants respectfully submit that all claims remaining in the application are now clearly allowable. Favorable consideration and a Notice of Allowance are earnestly solicited. Applicants' attorney wishes to express her willingness to engage in a telephone interview to further the status of this application if any further concerns need to be addressed.

Respectfully submitted,

Tongtong Wang et al.

Seed Intellectual Property Law Group PLLC



Carol D. Laherty, Ph.D.

Registration No. 51,909

CDL:sd

Enclosure:

Postcard

701 Fifth Avenue, Suite 6300
Seattle, Washington 98104-7092
Phone: (206) 622-4900
Fax: (206) 682-6031

D:\NrPortbl\iManage\SANDID\300460_1.DOC

VERSION WITH MARKINGS TO SHOW CHANGES MADE

In the Claims:

6. (Amended) A method for detecting the presence of a cancer in a patient, comprising the steps of:

- (a) obtaining a biological sample from the patient;
- (b) contacting the biological sample with a binding agent that binds to a polypeptide comprising at least 10 contiguous amino acid residues of a polypeptide encoded by the polynucleotide sequence of SEQ ID NO:808 of claim 2;
- (c) detecting in the sample an amount of polypeptide that binds to the binding agent; and
- (d) comparing the amount of polypeptide to a predetermined cut-off value and therefrom determining the presence of a cancer in the patient.